IBD

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated August 1, 2026

Overview

Evidence-based care for chronic intestinal conditions.

Metabolic Syndrome Is Becoming a Major Modifier of IBD Outcomes: UEG Journal | August 2026

Introduction: IBD is increasingly recognised as a systemic inflammatory disease, while obesity and metabolic syndrome are becoming progressively more common in the same population. This large real-world study examined how cardiometabolic disease in patients with...

Risankizumab Performs Well in Real-World Crohn’s Disease—even After Ustekinumab (ARISE-CD): BMJ Open | August 2026

Introduction: Risankizumab, an IL-23 p19 inhibitor, is established for moderately to severely active Crohn’s disease based on phase III trials. ARISE-CD examined how well it performs in routine practice, particularly in a difficult-to-treat population with...

Duvakitug - Anti-TL1A Therapy in IBD: The Lancet Gastroenterology & Hepatology | August 2026

Introduction: Despite an expanding range of advanced therapies for inflammatory bowel disease (IBD), many patients fail to achieve durable remission or lose response over time. TL1A is an attractive therapeutic target because it is implicated...

IBD in East and Southeast Asia: The Lancet Gastroenterology & Hepatology | August 2026

Introduction: Inflammatory bowel disease (IBD), historically concentrated in Western countries, is rapidly becoming a major healthcare challenge across East and Southeast Asia. This review examines a century of IBD evolution across Japan, South Korea, China,...

IUS Steroid Failure and Colectomy Risk in Pediatric ASUC: Gastroenterology | August 2026

Acute severe ulcerative colitis (ASUC) in children requires rapid identification of intravenous corticosteroid failure to avoid delayed rescue therapy and colectomy. Intestinal ultrasound (IUS) offers a noninvasive, repeatable bedside assessment of bowel inflammation. This prospective...

IUS For Detecting Postoperative Crohn's Disease Recurrence: The Lancet Gastroenterology & Hepatology | July 2026

Introduction: Endoscopic assessment remains the standard for detecting postoperative recurrence after ileocolic resection in Crohn's disease, but it is invasive and resource-intensive. This international multidisciplinary RAND/UCLA consensus developed standardised recommendations for the use of intestinal...

Diet and IBD Flares: Gut | July 2026

Introduction: Patients with inflammatory bowel disease (IBD) frequently ask whether diet influences disease relapse, yet high-quality prospective evidence has been scarce. The multicenter PREdiCCt study evaluated the impact of demographic, clinical, and habitual dietary factors...

Stopping Thiopurines After Starting Anti-TNF Therapy: CGH | July 2026

Introduction: Combination therapy with anti–tumor necrosis factor (anti-TNF) agents and thiopurines improves treatment efficacy in inflammatory bowel disease (IBD), but long-term thiopurine use raises concerns regarding infection and malignancy. This nationwide population-based study evaluated the...

Clinical Guideline Update: Management of Ulcerative Colitis in Adults from updated ACG Clinical Guideline: JAMA | July 2026

Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease characterized by relapsing and remitting colonic inflammation. The updated 2025 American College of Gastroenterology (ACG) Guideline emphasizes treat-to-target management, objective disease monitoring, and individualized selection of...

Alcohol Metabolism Determines IBD Risk: Gut | July 2026

Introduction: The relationship between alcohol consumption and inflammatory bowel disease (IBD) has remained controversial. This large prospective study demonstrates that the effect of alcohol depends on an individual's genetic capacity to metabolize acetaldehyde, highlighting a...

Intestinal Ultrasound for Monitoring IBD: JCC | July 2026

Introduction: Endoscopy remains the gold standard for assessing inflammatory bowel disease (IBD) activity but is invasive, costly, and resource-intensive. This real-world study evaluated whether integrating intestinal ultrasound (IUS) into routine IBD care could reduce the...

Beta-Glucan and Inulin in Crohn's Disease prevention: Gastroenterology | July 2026

Introduction: Diet plays an important role in the development of Crohn's disease (CD), but the effects of specific dietary fiber subtypes remain unclear. This prospective study evaluated whether individual fiber types influence the risk of...

Digital Twins in IBD: Gut | July 2026

Introduction: Clinical trials in inflammatory bowel disease (IBD) are becoming increasingly expensive, complex, and difficult to conduct. This review explores the emerging role of digital twins—virtual, data-driven replicas of individual patients—as a novel approach to...

Upadacitinib vs Tofacitinib: CGH | 2026

Introduction: Janus kinase (JAK) inhibitors have transformed the treatment of moderate-to-severe ulcerative colitis (UC), particularly in patients who have failed biologic therapies. However, direct comparisons between upadacitinib (UPA) and tofacitinib (TOFA) have been lacking. This...

IBD Across Ethnicities: Gastroenterology | July 2026

Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...

Moving Beyond the "Wait to Fail" Strategy in ASUC: FG | 2026

Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...

FMT in Ulcerative Colitis: JGH | July 2026

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...

Engineering Immune Cell Therapies for IBD: Nat Re Gastroe & Hepato | June 2026

Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...

Real-World IBD Patients Rarely Meet Clinical Trial Criteria: AJG | June 2026

Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...

Mirikizumab in Ulcerative Colitis: JCC | June 2026

Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...

Mirikizumab Shows Promising Real-World Effectiveness in Ulcerative Colitis: JCC | May 2026

Upadacitinib + Vedolizumab: CGH | June 2026

This multicenter randomized trial evaluated whether combining upadacitinib with vedolizumab during induction therapy could improve outcomes in moderate-to-severe ulcerative colitis. A total of 113 patients were randomized to receive either vedolizumab alone or vedolizumab plus...

Dose Escalation Offers Limited Benefit After Ustekinumab Failure : Gastroenterology | Jul 2026

Introduction: Ustekinumab is an established treatment for moderate-to-severe Crohn’s disease, but secondary loss of response remains a significant clinical challenge during long-term therapy. In routine practice, dose intensification strategies are frequently employed to recapture disease...

Subcutaneous Infliximab Achieves Higher Colonic Tissue Drug Levels Than Intravenous Therapy: UEG Journal | March 2026

Infliximab exerts its therapeutic effect within intestinal tissue, yet most therapeutic drug monitoring currently relies on serum concentrations. This study is the first to directly compare serum and colonic tissue infliximab concentrations between subcutaneous (SC)...

Ultraprocessed Grains Increase IBD Risk: AJG | June 2026

This large prospective PURE study evaluated the relationship between ultraprocessed grain consumption and the future development of inflammatory bowel disease across 124,590 participants from 21 countries. Ultraprocessed grains include heavily refined grain products that often...

HLA-DRB1*01:03 Identifies a Severe IBD Phenotype : Lancet Gastroenterol Hepatol | June 2026

Introduction: Inflammatory bowel disease (IBD) exhibits marked heterogeneity in disease behavior, progression, and treatment response. Identifying genetic markers associated with aggressive disease could facilitate earlier risk stratification and personalized therapeutic strategies. Among genetic factors, the...

Ustekinumab and Anti-TNFs Show Comparable Efficacy After Vedolizumab Failure : GETAID | June 2026

Introduction: Vedolizumab has become a widely used first-line advanced therapy for ulcerative colitis (UC) because of its favorable efficacy and safety profile. However, a substantial proportion of patients experience primary nonresponse or secondary loss of...

Metastatic Crohn’s Disease Often Precedes Intestinal Diagnosis : Gut | June 2026

Introduction: Metastatic Crohn’s disease (MCD), also referred to as cutaneous or genital Crohn’s disease, is a rare extraintestinal manifestation characterized by granulomatous skin inflammation occurring at sites separate from the gastrointestinal tract. Because of its...

Darvadstrocel in Complex Perianal Crohn’s Disease: Gastroenterology | June 2026

Darvadstrocel is an allogeneic adipose-derived mesenchymal stem cell therapy designed to promote fistula healing through anti-inflammatory and immunomodulatory mechanisms. It is administered locally into conditioned fistula tracts after curettage and closure of the internal opening....

Inflammaging and Sarcopenia: Nutrients | June 2026

Inflammaging and sarcopenia are two interconnected hallmarks of aging that contribute to frailty, disability, metabolic dysfunction, loss of independence, and reduced quality of life. Inflammaging refers to chronic low-grade systemic inflammation that develops with aging,...

Managing C. difficile Infection in Patients With IBD: Gastroenterology | May 2026

Clostridioides difficile infection (CDI) remains one of the most important triggers of disease flares, hospitalization, treatment failure, colectomy, and mortality in patients with inflammatory bowel disease. Every patient with IBD presenting with new or worsening...

Darvadstrocel Misses Primary Endpoint in Complex Perianal Crohn’s Disease : CGH | Jun 2026

Introduction: Complex perianal fistulas represent one of the most debilitating manifestations of Crohn’s disease, often causing chronic pain, drainage, recurrent infections, and substantial impairment in quality of life. Despite advances in biologic therapy, fistula healing...

Anti–IL-10 Autoantibodies Define a New Subgroup of IBD: NEJM | June 2026

This landmark study identifies neutralizing autoantibodies against interleukin-10 (IL-10) as a previously underrecognized mechanism driving inflammatory bowel disease. IL-10 is a critical anti-inflammatory cytokine that maintains intestinal immune tolerance. Genetic defects in the IL-10 pathway...

AI Reads Pediatric IBD Biopsies: Cellular and Molecular Gastro and Hepato | June 2026

Histopathology remains a cornerstone for diagnosing pediatric inflammatory bowel disease, but differentiating Crohn’s disease from ulcerative colitis can be challenging, especially in young children. This study evaluated whether artificial intelligence could automatically identify key histological...

Vitamin D Supplementation Improves Real-World IBD Outcomes : CGH | Jun 2026

Introduction: Vitamin D deficiency is highly prevalent among patients with inflammatory bowel disease (IBD) and has been associated with increased disease activity, impaired mucosal healing, reduced quality of life, and higher healthcare utilization. Beyond its...

Darvadstrocel Fails to Improve Remission in Complex Perianal Crohn’s Fistulas : Gastroenterology | June 2026

Introduction: Crohn's Disease–associated complex perianal fistulas remain one of the most difficult complications in inflammatory bowel disease management, causing major morbidity, impaired quality of life, and high rates of treatment failure. Mesenchymal stem-cell therapy emerged...

AI and Multi-Omics Redefine Postoperative Crohn’s Recurrence : Gut | 2026

Introduction Crohn's Disease postoperative recurrence remains one of the greatest challenges after intestinal resection, with endoscopic recurrence occurring in the majority of patients within the first year. Despite advances in biologic therapy and surgical technique,...

FIT Plus Calprotectin Improves Young-Onset GI Triage : Gut | May 2026

Introduction Inflammatory Bowel Disease and early-onset Colorectal Cancer are increasingly encountered in younger adults presenting with lower gastrointestinal symptoms. However, distinguishing inflammatory disease from neoplasia in this age group remains diagnostically challenging. Problem Statement The...

Upadacitinib–Vedolizumab Combination Breaks the UC Efficacy Ceiling : Gastroenterology | May 2026

Introduction Ulcerative Colitis treatment outcomes remain constrained by an “efficacy ceiling,” with most advanced therapies achieving endoscopic remission rates below 30%. Rapid induction of deep remission remains a major unmet need, particularly in patients with...

AI and Multi-Omics Redefine Postoperative Crohn’s Recurrence : Gut | May 2026

Introduction Crohn's Disease postoperative recurrence remains one of the greatest long-term challenges after intestinal resection, with endoscopic recurrence developing in a substantial proportion of patients within the first postoperative year. Despite advances in biologic therapy...

International Consensus Defines the Role of Intestinal Ultrasound in Postoperative Crohn’s Disease Surveillance : Lancet Gastroenterol Hepatol | May 2026

Introduction Crohn's Disease recurrence after ileocolic resection remains common, with postoperative endoscopic recurrence often preceding clinical symptoms. Early identification of recurrence is critical because timely therapeutic escalation may prevent progression to stricturing disease, repeat surgery...

Real-World Risankizumab Outcomes in Refractory CD : Frontline Gastroenterol | May 2026

Introduction Risankizumab is a selective interleukin-23 p19 inhibitor approved for moderate-to-severe Crohn’s Disease following strong efficacy signals in phase III trials. However, real-world evidence in heavily pretreated Crohn’s disease populations, particularly after prior biologic and...

Upadacitinib Shows Real-World Benefit in Perianal Crohn’s Disease : Clin Gastroenterol Hepatol | May 2026

Introduction Perianal Crohn’s Disease remains one of the most disabling and treatment-refractory manifestations of inflammatory bowel disease, frequently associated with fistulas, abscesses, recurrent surgery and impaired quality of life. Although anti-TNF therapy has historically been...

FIT Pathways Frequently Identify IBD in Younger Patients : Br J Surg | May 2026

Introduction Inflammatory bowel disease and Colorectal Cancer frequently present with overlapping lower gastrointestinal symptoms including rectal bleeding, altered bowel habits and abdominal pain. In the UK, symptomatic Faecal immunochemical testing is widely used in primary...

Upadacitinib in Perianal Crohn’s Disease: CGH | May 2026

Introduction Perianal Crohn’s disease (pCD) remains one of the most challenging manifestations of inflammatory bowel disease, often associated with fistulas, recurrent infections, impaired quality of life, and repeated surgeries. Although anti-TNF agents have been the...

Vaccination Uptake Remains Poor in Immunosuppressed IBD Patients : Frontline Gastroenterol | May 2026

Introduction Inflammatory bowel disease patients receiving immunosuppressive therapy are at increased risk of vaccine-preventable infections, including influenza, pneumococcal disease and COVID-19. International guidelines strongly recommend routine immunization in this vulnerable population, yet real-world vaccine adherence...

A Pragmatic Prevention Framework for IBD in the Global South : Gut | 2026

Introduction Inflammatory bowel disease is rapidly emerging as a global disease, with rising incidence across low-income and middle-income countries. Although biologics and small-molecule therapies have transformed disease outcomes, long-term treatment remains costly, infrastructure-intensive and difficult...

Jejunal Feeding Challenges in DGBI and GI Dysmotility : Frontline Gastroenterol | May 2026

Introduction Patients with disorders of gut–brain interaction (DGBI) and gastrointestinal dysmotility (GID) frequently experience severe nutritional compromise requiring enteral support. Jejunal feeding is often considered in patients unable to maintain adequate oral intake, particularly when...

Personalized Infliximab Dosing in ASUC: JCC | March 2026

Introduction Acute severe ulcerative colitis (ASUC) is a life-threatening condition requiring urgent treatment. In patients who fail steroids, Infliximab is widely used as rescue therapy. However, response is highly variable, and a significant proportion of...

Statins Reduce Stricture Risk in Crohn’s Disease: JCC | March 2026

Introduction Stricture formation is a major complication of Crohn’s disease, affecting more than half of patients and often leading to obstruction, repeated hospitalizations, and need for surgery. Current therapies primarily target inflammation, but effective strategies...

Colitis-Associated CRC: Nature Reviews Gastroent & Hepatol | April 2026

Introduction Colitis-associated colorectal cancer (caCRC) represents a distinct subtype of colorectal cancer that develops in patients with long-standing Inflammatory Bowel Disease, particularly Ulcerative Colitis and Crohn’s Disease. With the rising global burden of IBD, the...

Multiomic Insights into Guselkumab Response in UC: BMJ Open Gastroenterology | March 2026

Introduction Ulcerative colitis is a chronic inflammatory disorder driven by dysregulated immune pathways, with the interleukin-23 (IL-23)/Th17 axis playing a central pathogenic role. Modern treatment strategies have shifted toward achieving deep remission, including histological and...

Colorectal Surveillance in IBD: Updated BSG Guidance: Gut | 2026

Introduction The updated British Society of Gastroenterology guideline reflects an important change in the way we think about colorectal cancer surveillance in inflammatory bowel disease. The modern message is not that every patient with colonic...

JAK Inhibitors in ASUC: A Systematic Review: AJG March 2026

Acute severe ulcerative colitis (ASUC) is a life-threatening complication of ulcerative colitis that often requires hospitalisation and urgent therapy. Although intravenous corticosteroids remain the standard first-line treatment, a significant proportion of patients fail to respond...

Mirikizumab in Paediatric UC (SHINE-1 Trial): Lancet Gastroentrol Hepatolo, February 2026

Introduction Ulcerative colitis (UC) in children is often aggressive and difficult to manage, with many patients failing conventional therapies such as corticosteroids, immunomodulators, biologics, or JAK inhibitors. Mirikizumab, a humanised monoclonal antibody targeting the p19...

ACCURE Trial (Appendectomy and UC): Lancet Gastro Hepato, March 2026

The ACCURE randomised clinical trial investigated whether laparoscopic appendicectomy could improve disease outcomes in ulcerative colitis (UC) when added to standard medical therapy. The rationale for this approach stems from evidence suggesting that the appendix...

Vedolizumab and Pregnancy: Am J Gastro, March 2026

Vedolizumab, a gut-selective monoclonal antibody targeting α4β7 integrin, is widely used for the treatment of Crohn’s disease and ulcerative colitis, but safety data during pregnancy have been limited. This prospective observational study from the Vedolizumab...

Mediterranean Diet in IBD: IJG March 2026

Introduction Diet plays an important role in the pathogenesis and management of inflammatory bowel disease (IBD). Among various dietary patterns, the Mediterranean diet (MD)—rich in fruits, vegetables, whole grains, olive oil, legumes, nuts, and fish—has...

Microbiome Signature at IBD Onset: Gastroenterology | March 2026

Introduction Most microbiome studies in inflammatory bowel disease (IBD) are confounded by prior treatment, long disease duration, and inconsistent sequencing/bioinformatic methods—making “core” signatures hard to trust. This systematic review tackles a key unmet question: what...

Faecal S100A9- A new IBD Biomarker: Gastroenterology | March 2026

Why Look Beyond Fecal Calprotectin? Fecal calprotectin (FC) is one of the most widely used noninvasive biomarkers in inflammatory bowel disease (IBD). It reflects intestinal inflammation through the detection of the S100A8/S100A9 heterotetramer, released primarily...

A Normal UCEIS Is Zero, not Three: Gastroenterology | March 26

Introduction The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) was developed to standardise the endoscopic assessment of ulcerative colitis activity. It evaluates vascular pattern, bleeding, and erosions/ulcers, generating a score reflecting disease severity. Although initially...

VECTORS Trial - BMJ Open Gastro Feb. 26

The VECTORS trial, a landmark phase 4 randomized controlled trial (RCT), was recently published in BMJ Open Gastroenterology on February 26. This trial represents a significant step forward in the treatment of Crohn’s disease (CD)...

Caffeine and IBD - JGH Feb 26

This is the first comprehensive meta-analysis examining the relationship between caffeine intake and inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), synthesising data from 21 studies (13,209 participants). Overall, caffeine intake...

Subcutaneous Guselkumab for Crohn’s: Interpreting GRAVITI Carefully- Gastroenterology Feb.26

Introduction Fully subcutaneous biologic regimens are attractive in Crohn’s disease because they can reduce infusion burden and improve convenience. The GRAVITI trial evaluated a fully subcutaneous induction and maintenance strategy with guselkumab (IL-23p19) and reported...

Inpatient IBD Care: Practical Guidance From the AGA- Gastroenterology Feb.26

Introduction Despite major advances in outpatient therapies, hospitalisation for inflammatory bowel disease (IBD) remains common and challenging. Outcomes vary widely, with persistent problems such as: hospital-acquired complications, delays in appropriate surgery, and high 30-day readmission...

From Treatment to Prevention in IBD - Gastroenterology Feb.26

Introduction Inflammatory bowel disease (IBD) is no longer a condition confined to Western countries. With globalisation, urbanisation, and changing environmental exposures, IBD incidence is rising worldwide, while prevalence in industrialised nations continues to compound. If...

Nutrition management puzzle in IBD- Front. Med. 2026

Nutritional Management in IBD: Current Insights Importance of Nutrition in IBD: Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is influenced by genetic, immunological, environmental, and gut microbiota factors. Nutrition...

The PIONIR Trial - Gut Jan. 2026

The PIONIR (Preventing IBD ONset in Individuals at Risk) trial, as described in the study published in Gut, January 2026, focuses on evaluating whether the Tasty&Healthy diet can reduce the risk of developing Crohn’s disease...

Biological and chronic pouchitis (AP&T) - Jan,2026

I am unable to provide information from the future (e.g., January 2026) as my training data only includes content up to October 2023. However, I can provide you with detailed insights into the role of...

SHINE -1 - Mirikizumab in UC

The SHINE-1 trial was a multicentre, open-label, non-randomised phase 2 study designed to evaluate the efficacy, safety, and pharmacokinetics of mirikizumab in paediatric participants aged 2 to <18 years with moderately-to-severely active ulcerative colitis (UC)....

Etrasimod for the symptomatic relief of ulcerative colitis

Etrasimod is a novel oral medication approved for the treatment of moderately to severely active ulcerative colitis (UC). It is a selective sphingosine 1-phosphate (S1P) receptor modulator that targets S1P receptors 1, 4, and 5,...

Cardiovascular events observed among patients in the etrasimod clinical programme

The cardiovascular events observed among patients in the etrasimod clinical program were evaluated as part of an integrated safety analysis, focusing on treatment-emergent adverse events (TEAEs) associated with etrasimod. Here are the detailed findings: Bradycardia:...

QUOTIENT Trial: Treat-to-Target Endoscopic Remission in IBD on Advanced Therapies

The QUality Outcomes Treating IBD to Target (QUOTIENT) trial is a significant, pragmatic, open-label, multicentre randomised controlled study that addresses a critical question in the management of inflammatory bowel disease (IBD), which includes Crohn’s disease...

Biologic Switch Timing and Infection Risk in Ulcerative Colitis and Crohn’s Disease

The study in question investigates the timing of biologic switches and their impact on infection risk in patients with Ulcerative Colitis (UC) and Crohn’s Disease (CD). It specifically examines the difference in infection risk between...

Fecal Calprotectin Reflects Disease Extent and Mucosal Healing in Ulcerative Colitis

Yes, fecal calprotectin (FC) reflects both disease extent and mucosal healing in ulcerative colitis (UC), as demonstrated by the findings of the prospective observational study mentioned in the context. Here's a detailed explanation based on...

Long-Term Safety of Mirikizumab in Moderate-to-Severe Ulcerative Colitis

The long-term safety of mirikizumab, an anti–interleukin-23p19 monoclonal antibody, for the treatment of moderately to severely active ulcerative colitis was evaluated over a 2-year period of continuous treatment. This analysis pooled data from three phase...

Patient Risk Tolerance for Dual Biologic Therapy in Inflammatory Bowel Disease

The study on patient risk tolerance for dual biologic therapy (DBT) in inflammatory bowel disease (IBD) revealed several important insights into how patients with Crohn's disease (CD) and ulcerative colitis (UC) weigh the benefits and...

Diagnostic Accuracy of Noninvasive Biomarkers and Imaging for Postoperative Crohn’s Disease Recurrence

The diagnostic accuracy of noninvasive biomarkers and imaging for detecting postoperative Crohn’s disease recurrence has been extensively studied and compared to the gold standard, ileocolonoscopy. Below is a detailed breakdown of the findings: C-Reactive Protein...

Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease

The real-world effectiveness and safety of upadacitinib in Crohn’s disease were assessed in a multicenter retrospective study involving 9 tertiary inflammatory bowel disease (IBD) centers across North America. This study provided insights into the use...

AGA Living Guideline on Pharmacologic Management of Moderate-to-Severe Crohn’s Disease

The American Gastroenterological Association (AGA) Living Guideline on the pharmacologic management of moderate-to-severe Crohn’s disease provides evidence-based recommendations to guide clinical decision-making for adult outpatients with moderate-to-severely active luminal Crohn’s disease. The guideline focuses on...

Whole Food Diet Induces Remission in Pediatric and Young Adult Crohn’s Disease

Yes, a whole food diet, specifically the Tasty&Healthy (T&H) diet, has been shown to induce remission in pediatric and young adult patients with mild to moderate Crohn’s disease. Here's a detailed explanation based on the...

International Consensus on Corticosteroid Use in IBD Clinical Trials

The International Consensus on Corticosteroid Use in Inflammatory Bowel Disease (IBD) Clinical Trials represents the first global, expert-driven guidance to standardize corticosteroid management in IBD drug trials. This guidance aims to address the challenges and...

The adoption of a westernized gut microbiome in Indian Immigrants and Indo-Canadians is associated with dietary acculturation

Yes, the adoption of a westernized gut microbiome in Indian immigrants and Indo-Canadians is strongly associated with dietary acculturation. The study highlights that dietary acculturation—defined as the shift from traditional dietary practices to the consumption...

Interplay between creeping fat and gut microbiota: A brand-new perspective on fecal microbiota transplantation in Crohn’s disease

The interplay between creeping fat (CrF) and gut microbiota offers a novel perspective on the use of fecal microbiota transplantation (FMT) in Crohn's disease (CD). Creeping fat, a hallmark feature of CD, is a specific...

Prediction and Prevention of Inflammatory Bowel Disease

The prediction and prevention of Inflammatory Bowel Disease (IBD) represent a transformative approach to addressing the challenges posed by this chronic, immune-mediated condition. IBD, which primarily includes Crohn's disease and ulcerative colitis, is characterized by...

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis

The study you are referring to explores the relationship between the inflammatory potential of overall dietary patterns and the risk of developing inflammatory bowel diseases (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC). Here's...

ultraprocessed grains and IBD

The relationship between ultraprocessed grains and inflammatory bowel disease (IBD) has been examined in the context of the Prospective Urban Rural Epidemiology (PURE) study. This study highlights a significant association between the consumption of ultraprocessed...

Global evolution of inflammatory bowel disease across epidemiologic stages

The global evolution of inflammatory bowel disease (IBD) can be understood through its progression across four distinct epidemiologic stages, which reflect the changing patterns of incidence, prevalence, and disease burden over time. This evolution is...

Diagnostic performance of intestinal ultrasound compared with CT enterography in Crohn’s disease: single-center experience

The study conducted a retrospective single-center analysis to evaluate the diagnostic performance of transabdominal bowel ultrasonography (TBUS) compared with computed tomography enterography (CTE) in identifying intestinal lesions and complications in patients with Crohn’s disease (CD)....

Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe UC

The meta-analysis conducted on randomized controlled trials provides comprehensive insights into the efficacy and safety of IL-23 inhibitors for the treatment of moderate to severe ulcerative colitis (UC). Below is a detailed summary of the...

Upadacitinib in a real-world data from UK

The real-world data on the use of upadacitinib for Crohn’s disease (CD) in the UK provides valuable insights into its effectiveness and safety in a challenging, clinically refractory patient population. Here is a detailed summary...

single-wavelength endoscopy technology in UC

Single-wavelength endoscopy (SWE) is an advanced imaging technology that uses light of a specific wavelength to enhance visualization of tissue characteristics during endoscopic procedures. In the context of ulcerative colitis (UC), a chronic inflammatory bowel...

ESD for high-risk colorectal colitis-associated neoplasia in IBD

Endoscopic submucosal dissection (ESD) has emerged as a highly effective and safe treatment for high-risk colorectal colitis-associated neoplasia (HR-CAN) in patients with inflammatory bowel disease (IBD), according to a multicenter Italian study. HR-CAN in IBD...

A Consensus Blueprint for Steroid Stewardship in IBD Trials

The "Consensus Blueprint for Steroid Stewardship in IBD Trials" is a globally agreed-upon framework developed by a panel of 45 international experts through the Delphi process to standardize and optimize the use of steroids in...

Noninvasive Imaging in and IBD

Noninvasive imaging techniques are revolutionizing the diagnosis, monitoring, and management of inflammatory bowel disease (IBD), which includes conditions like Crohn’s disease (CD) and ulcerative colitis (UC). These methods are increasingly favored for their ability to...

Corticosteroids in Clinical Trials in Inflammatory Bowel Disease

Corticosteroids play a significant role in managing inflammatory bowel disease (IBD), but their use in clinical trials has been inconsistent, leading to challenges in interpreting study outcomes. To address this issue, an international consensus was...

GI infections and IBD Flare

Gastrointestinal (GI) infections are closely linked to flare-ups in inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. Here’s a detailed breakdown of the relationship between GI infections and IBD flares: Increased Risk of...

Monogenic Verus Polygenic IBD

Inflammatory Bowel Disease (IBD) is a chronic condition characterized by inflammation in the gastrointestinal tract. It is broadly categorized into two main types: Crohn's Disease (CD) and Ulcerative Colitis (UC). IBD is a complex disorder...

IL-23 inhibitors and IBD

IL-23 inhibitors represent a significant advancement in the treatment landscape for inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC). These biologic agents target the interleukin-23 (IL-23) cytokine, specifically its p19...

Gut inflammation and axial spondyloarthritis –SPARTAKUS cohor

The relationship between gut inflammation and axial spondyloarthritis (axSpA) has been extensively studied, and the SPARTAKUS cohort plays a key role in advancing our understanding of this association. Below is a detailed explanation of the...

Oral lyophilized donor FMT in ulcerative colitis

Oral Lyophilized Donor FMT in Ulcerative Colitis: Oral lyophilized donor fecal microbiota transplantation (FMT) involves encapsulated, freeze-dried fecal microbiota from a healthy donor, designed for oral administration. This innovative approach simplifies the logistics of FMT...

Upadacitinib in a real-world cohort of patients with Crohn’s disease in the UK

The real-world study on upadacitinib in patients with moderate-to-severe Crohn’s disease (CD) was conducted across 19 hospitals in the UK between April and October 2023. The study aimed to evaluate the effectiveness, persistence, and safety...

Psychological interventions and IBD Management

Psychological interventions have been increasingly recognized as valuable components in the management of inflammatory bowel disease (IBD). This is because IBD is not only a physical condition but also closely intertwined with psychological and emotional...

Therapy of iPSC-derived CD146+ mesenchymal stem cells in ulcerative colitis

The study explored the therapeutic potential of induced pluripotent stem cell-derived CD146+ mesenchymal stem cells (CD146+iMSCs) for treating ulcerative colitis (UC). These stem cells were compared to CD146+ umbilical cord mesenchymal stem cells (UCMSCs) in...

Decoding IBD progression

Decoding Inflammatory Bowel Disease (IBD) progression involves understanding how gut microbiota and host genetic changes correlate with disease severity. A recent study developed a multi-omics framework combining gut microbiota profiling (via fecal 16S rRNA sequencing)...

Ustekinumab trough level and perianal fistulizing Crohn’s disease

In the context of perianal fistulizing Crohn's disease (PFCD), ustekinumab (UST) trough concentrations play a critical role in predicting clinical and radiological remission. A recent study has identified optimal trough levels for achieving fistula remission...

Novel antibiotic targets IBD—and AI

The novel antibiotic targeting inflammatory bowel disease (IBD) is called enterololin, and it represents a groundbreaking achievement in medical research, combining cutting-edge artificial intelligence (AI) with pharmacological science. Here's a detailed breakdown of its significance...

Extended risankizumab treatment for Crohn’s disease

Extended risankizumab (RZB) therapy has shown promising results for Crohn’s disease patients who fail to respond to the standard 12-week induction phase. Phase 3 trials (ADVANCE, MOTIVATE, FORTIFY) evaluated the efficacy of an additional 12...

Fidaxomicin and Crohn's Disease

Fidaxomicin has emerged as a promising therapeutic candidate for intestinal fibrosis in Crohn’s disease, a condition where up to 50% of patients develop strictures due to excessive collagen deposition and tissue scarring. Currently, no antifibrotic...

FACILE Classification: A New Era in IBD

The FACILE Classification represents a groundbreaking advancement in the way Inflammatory Bowel Disease (IBD), including Crohn's Disease (CD) and Ulcerative Colitis (UC), is categorized. Moving beyond traditional frameworks like the Montreal Classification, it introduces a...